Global Oncology Immuno Drug Market Insights, Forecast to 2028

Table Of Contents

1 Study Coverage

1.1 Oncology Immuno Drug Product Introduction 1.2 Market by Type 1.2.1 Global Oncology Immuno Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Immune Checkpoint Inhibitors 1.2.3 Cytokine-Based Immunotherapy 1.2.4 Cancer Vaccines 1.2.5 CAR-T Cell Therapy 1.2.6 Other 1.3 Market by Application 1.3.1 Global Oncology Immuno Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Drugstores 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered2 Executive Summary 2.1 Global Oncology Immuno Drug Sales Estimates and Forecasts 2017-2028 2.2 Global Oncology Immuno Drug Revenue Estimates and Forecasts 2017-2028 2.3 Global Oncology Immuno Drug Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global Oncology Immuno Drug Sales by Region 2.4.1 Global Oncology Immuno Drug Sales by Region (2017-2022) 2.4.2 Global Sales Oncology Immuno Drug by Region (2023-2028) 2.5 Global Oncology Immuno Drug Revenue by Region 2.5.1 Global Oncology Immuno Drug Revenue by Region (2017-2022) 2.5.2 Global Oncology Immuno Drug Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa3 Competition by Manufacturers 3.1 Global Oncology Immuno Drug Sales by Manufacturers 3.1.1 Global Top Oncology Immuno Drug Manufacturers by Sales (2017-2022) 3.1.2 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oncology Immuno Drug in 2021 3.2 Global Oncology Immuno Drug Revenue by Manufacturers 3.2.1 Global Oncology Immuno Drug Revenue by Manufacturers (2017-2022) 3.2.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by Oncology Immuno Drug Revenue in 2021 3.3 Global Oncology Immuno Drug Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Oncology Immuno Drug Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans4 Market Size by Type 4.1 Global Oncology Immuno Drug Sales by Type 4.1.1 Global Oncology Immuno Drug Historical Sales by Type (2017-2022) 4.1.2 Global Oncology Immuno Drug Forecasted Sales by Type (2023-2028) 4.1.3 Global Oncology Immuno Drug Sales Market Share by Type (2017-2028) 4.2 Global Oncology Immuno Drug Revenue by Type 4.2.1 Global Oncology Immuno Drug Historical Revenue by Type (2017-2022) 4.2.2 Global Oncology Immuno Drug Forecasted Revenue by Type (2023-2028) 4.2.3 Global Oncology Immuno Drug Revenue Market Share by Type (2017-2028) 4.3 Global Oncology Immuno Drug Price by Type 4.3.1 Global Oncology Immuno Drug Price by Type (2017-2022) 4.3.2 Global Oncology Immuno Drug Price Forecast by Type (2023-2028)5 Market Size by Application 5.1 Global Oncology Immuno Drug Sales by Application 5.1.1 Global Oncology Immuno Drug Historical Sales by Application (2017-2022) 5.1.2 Global Oncology Immuno Drug Forecasted Sales by Application (2023-2028) 5.1.3 Global Oncology Immuno Drug Sales Market Share by Application (2017-2028) 5.2 Global Oncology Immuno Drug Revenue by Application 5.2.1 Global Oncology Immuno Drug Historical Revenue by Application (2017-2022) 5.2.2 Global Oncology Immuno Drug Forecasted Revenue by Application (2023-2028) 5.2.3 Global Oncology Immuno Drug Revenue Market Share by Application (2017-2028) 5.3 Global Oncology Immuno Drug Price by Application 5.3.1 Global Oncology Immuno Drug Price by Application (2017-2022) 5.3.2 Global Oncology Immuno Drug Price Forecast by Application (2023-2028)6 North America 6.1 North America Oncology Immuno Drug Market Size by Type 6.1.1 North America Oncology Immuno Drug Sales by Type (2017-2028) 6.1.2 North America Oncology Immuno Drug Revenue by Type (2017-2028) 6.2 North America Oncology Immuno Drug Market Size by Application 6.2.1 North America Oncology Immuno Drug Sales by Application (2017-2028) 6.2.2 North America Oncology Immuno Drug Revenue by Application (2017-2028) 6.3 North America Oncology Immuno Drug Market Size by Country 6.3.1 North America Oncology Immuno Drug Sales by Country (2017-2028) 6.3.2 North America Oncology Immuno Drug Revenue by Country (2017-2028) 6.3.3 United States 6.3.4 Canada7 Europe 7.1 Europe Oncology Immuno Drug Market Size by Type 7.1.1 Europe Oncology Immuno Drug Sales by Type (2017-2028) 7.1.2 Europe Oncology Immuno Drug Revenue by Type (2017-2028) 7.2 Europe Oncology Immuno Drug Market Size by Application 7.2.1 Europe Oncology Immuno Drug Sales by Application (2017-2028) 7.2.2 Europe Oncology Immuno Drug Revenue by Application (2017-2028) 7.3 Europe Oncology Immuno Drug Market Size by Country 7.3.1 Europe Oncology Immuno Drug Sales by Country (2017-2028) 7.3.2 Europe Oncology Immuno Drug Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia8 Asia Pacific 8.1 Asia Pacific Oncology Immuno Drug Market Size by Type 8.1.1 Asia Pacific Oncology Immuno Drug Sales by Type (2017-2028) 8.1.2 Asia Pacific Oncology Immuno Drug Revenue by Type (2017-2028) 8.2 Asia Pacific Oncology Immuno Drug Market Size by Application 8.2.1 Asia Pacific Oncology Immuno Drug Sales by Application (2017-2028) 8.2.2 Asia Pacific Oncology Immuno Drug Revenue by Application (2017-2028) 8.3 Asia Pacific Oncology Immuno Drug Market Size by Region 8.3.1 Asia Pacific Oncology Immuno Drug Sales by Region (2017-2028) 8.3.2 Asia Pacific Oncology Immuno Drug Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 China Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia9 Latin America 9.1 Latin America Oncology Immuno Drug Market Size by Type 9.1.1 Latin America Oncology Immuno Drug Sales by Type (2017-2028) 9.1.2 Latin America Oncology Immuno Drug Revenue by Type (2017-2028) 9.2 Latin America Oncology Immuno Drug Market Size by Application 9.2.1 Latin America Oncology Immuno Drug Sales by Application (2017-2028) 9.2.2 Latin America Oncology Immuno Drug Revenue by Application (2017-2028) 9.3 Latin America Oncology Immuno Drug Market Size by Country 9.3.1 Latin America Oncology Immuno Drug Sales by Country (2017-2028) 9.3.2 Latin America Oncology Immuno Drug Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina10 Middle East and Africa 10.1 Middle East and Africa Oncology Immuno Drug Market Size by Type 10.1.1 Middle East and Africa Oncology Immuno Drug Sales by Type (2017-2028) 10.1.2 Middle East and Africa Oncology Immuno Drug Revenue by Type (2017-2028) 10.2 Middle East and Africa Oncology Immuno Drug Market Size by Application 10.2.1 Middle East and Africa Oncology Immuno Drug Sales by Application (2017-2028) 10.2.2 Middle East and Africa Oncology Immuno Drug Revenue by Application (2017-2028) 10.3 Middle East and Africa Oncology Immuno Drug Market Size by Country 10.3.1 Middle East and Africa Oncology Immuno Drug Sales by Country (2017-2028) 10.3.2 Middle East and Africa Oncology Immuno Drug Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia11 Company Profiles 11.1 Bristol-Myers Squibb 11.1.1 Bristol-Myers Squibb Corporation Information 11.1.2 Bristol-Myers Squibb Overview 11.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Bristol-Myers Squibb Recent Developments 11.2 Merck & Co 11.2.1 Merck & Co Corporation Information 11.2.2 Merck & Co Overview 11.2.3 Merck & Co Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 Merck & Co Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 Merck & Co Recent Developments 11.3 Roche AG 11.3.1 Roche AG Corporation Information 11.3.2 Roche AG Overview 11.3.3 Roche AG Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.3.4 Roche AG Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.3.5 Roche AG Recent Developments 11.4 AstraZeneca 11.4.1 AstraZeneca Corporation Information 11.4.2 AstraZeneca Overview 11.4.3 AstraZeneca Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.4.4 AstraZeneca Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.4.5 AstraZeneca Recent Developments 11.5 Sanofi S.A. 11.5.1 Sanofi S.A. Corporation Information 11.5.2 Sanofi S.A. Overview 11.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.5.4 Sanofi S.A. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.5.5 Sanofi S.A. Recent Developments 11.6 Dendreon Pharmaceuticals 11.6.1 Dendreon Pharmaceuticals Corporation Information 11.6.2 Dendreon Pharmaceuticals Overview 11.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.6.5 Dendreon Pharmaceuticals Recent Developments 11.7 Novartis 11.7.1 Novartis Corporation Information 11.7.2 Novartis Overview 11.7.3 Novartis Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.7.4 Novartis Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.7.5 Novartis Recent Developments 11.8 Gilead Sciences Inc. 11.8.1 Gilead Sciences Inc. Corporation Information 11.8.2 Gilead Sciences Inc. Overview 11.8.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.8.4 Gilead Sciences Inc. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.8.5 Gilead Sciences Inc. Recent Developments 11.9 Merck KGaA 11.9.1 Merck KGaA Corporation Information 11.9.2 Merck KGaA Overview 11.9.3 Merck KGaA Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2017-2022) 11.9.4 Merck KGaA Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications 11.9.5 Merck KGaA Recent Developments12 Industry Chain and Sales Channels Analysis 12.1 Oncology Immuno Drug Industry Chain Analysis 12.2 Oncology Immuno Drug Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Oncology Immuno Drug Production Mode & Process 12.4 Oncology Immuno Drug Sales and Marketing 12.4.1 Oncology Immuno Drug Sales Channels 12.4.2 Oncology Immuno Drug Distributors 12.5 Oncology Immuno Drug Customers13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Oncology Immuno Drug Industry Trends 13.2 Oncology Immuno Drug Market Drivers 13.3 Oncology Immuno Drug Market Challenges 13.4 Oncology Immuno Drug Market Restraints14 Key Findings in The Global Oncology Immuno Drug Study15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer